PO Box 1488
Warrenville, IL 60555
Phone: 331.248.7888
Email: sidp@affinity-strategies.com
Drs. Yohei Doi and Emily Heil join Dr. Erin McCreary to dive into one of the most requested topics from our listeners and something that is consistently confusing in clinical practice: Acinetobacter baumannii! Hear from experts on their experience with treating this tricky organism and their thoughts on best approaches when you are presented with CRAB.
References:
- SNAP doi:10.1128/mbio.02759-2
- ATTACK doi:10.1016/S1473-3099(23)00184-6
- CRAB among COVID patients: doi:10.1093/jac/dkad042
Transcript
Yohei Doi, MD, PhD
Dr. Yohei Doi is a professor of medicine at the University of Pittsburgh and the chair for the Antibacterial Resistance Leadership Group’s (ARLG) Gram Negative Committee. He also serves as the director for Center of Innovation Antimicrobial Therapy (CIAT) at the University of Pittsburgh and is a professor and Chair of Microbiology and Infectious Diseases at Fujada Health University in Japan. His primary topics of research include the genetic and molecular basis of emerging antimicrobial resistance mechanisms in Gram negative pathogens, early stage drug discovery against resistant pathogens, and clinical studies of resistant Gram negative infections including Acinetobacter.
Emily Heil PharmD, MS, FIDP, BCIDP, AAHIVP
Dr. Emily Heil is a professor in the Department of Practice Sciences and Health Outcomes Research at the University of Maryland School of Pharmacy, and she serves as a coordinator of the Antimicrobial Stewardship Program at the University of Maryland Medical Center. She currently chairs the SIDP International Task Force and is a past board member of SIDP. Dr. Heil is also currently serving as an author on the IDSA Guidance for the Treatment of Gram Negative Infections.
